For several years, Michael Jackson, Ph.D. senior vice president of drug discovery and development at Sanford Burnham Prebys’ Conrad Prebys Center for Chemical Genomics and co-principal investigator Lawrence Barak, M.D., Ph.D. at Duke University, have been developing a completely new class of drugs that works by targeting a receptor on neuron called neurotensin 1 receptor or NTSR1, that regulates dopamine release.
The researchers recently received a $6.3 million award from NIH and NIDA to advance their addiction drug candidate, called SBI-810, to the clinic.
Негізгі бет Michael Jackson discusses the potential of a truly new, first-in-class treatment for addiction
Пікірлер